This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reubi, J. C. Articles by Rehfeld, J. F. Search for Related Content PubMed PubMed Citation Articles by Reubi, J. C. Articles by Rehfeld, J. F.

Procholecystokinin as Marker of Human Ewing Sarcomas

¹ Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, Switzerland; ² Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Denmark; and ³ Institute of Medical Oncology, Inselspital, Berne, Switzerland

Purpose: Ewing sarcoma is a rapidly growing mesenchymal tumor in young adults. Although it was shown previously to express the cholecystokinin (CCK) gene, it is unknown whether CCK gene expression is detectable at protein level in Ewing sarcoma tumor cell lines, in tumor tissue, and in plasma from Ewing sarcoma patients, and, if so, whether CCK peptides might play a role as tumor markers.

Experimental Design: CCK gene expression was evaluated with in situ hybridization or reverse transcription-PCR in tumor tissue. CCK precursors and bioactive CCK were measured with specific RIAs in tumor tissue, in cell culture medium, and in plasma of Ewing sarcoma patients before and after chemotherapy as well as after tumor recurrence.

Results: CCK mRNA was identified in 12 Ewing sarcoma biopsies sampled in two series and in four Ewing sarcoma cell lines but not in unrelated neoplasia. Immunoreactive proCCK was identified in the culturing medium of all Ewing sarcoma cell lines but not in the media from unrelated tumor cell lines. Moreover, in plasma from Ewing sarcoma patients, precursors and mature forms of CCK, in particular proCCK, were detected; several fold elevation of the total proCCK product was found in plasma from patients before treatment and after tumor recurrence, whereas successful chemotherapy reduced proCCK to basal concentrations. Plasma concentrations of proCCK paralleled the respective tumor size.

Conclusions: This is the first study that consistently documents an altered CCK metabolism in human cancer; Ewing sarcomas synthesize and secrete proCCK that can be identified in plasma as circulating tumor marker.

This article has been cited by other articles:

				J. Carrillo, E. Garcia-Aragoncillo, D. Azorin, N. Agra, A. Sastre, I. Gonzalez-Mediero, P. Garcia-Miguel, A. Pestana, S. Gallego, D. Segura, et al. Cholecystokinin Down-Regulation by RNA Interference Impairs Ewing Tumor Growth Clin. Cancer Res., April 15, 2007; 13(8): 2429 - 2440. [Abstract] [Full Text] [PDF]

				T. Borglum, J. F. Rehfeld, L. B. Drivsholm, and L. Hilsted Processing-Independent Quantitation of Chromogranin A in Plasma from Patients with Neuroendocrine Tumors and Small-Cell Lung Carcinomas Clin. Chem., March 1, 2007; 53(3): 438 - 446. [Abstract] [Full Text] [PDF]